{ "version": "https://jsonfeed.org/version/1.1", "title": "GLP-1 Tirzepatide Review", "home_page_url": "https://glp1tirzepatidereview.com", "feed_url": "https://glp1tirzepatidereview.com/feed.json", "description": "Independent evidence, pricing and provider research on tirzepatide and GLP-1 care.", "language": "en-US", "authors": [ { "name": "S.J Partners LLC", "url": "https://glp1tirzepatidereview.com" } ], "items": [ { "id": "https://glp1tirzepatidereview.com/news/fda-503b-bulks-exclusion-proposal/", "url": "https://glp1tirzepatidereview.com/news/fda-503b-bulks-exclusion-proposal/", "title": "FDA Proposes Permanent Exclusion of Semaglutide, Tirzepatide and Liraglutide From the 503B Bulks List", "summary": "The agency found no clinical need for outsourcing facilities to compound these drugs from bulk substances. If finalised, it closes the last pathway for compounding at scale.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/fda-comment-period-extension-503b/", "url": "https://glp1tirzepatidereview.com/news/fda-comment-period-extension-503b/", "title": "Comment Period on the GLP-1 Bulks Proposal Extended to 30 July", "summary": "FDA granted a 60-day extension after a request for more time. The window now closes days from publication, with no final determination in sight.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/fda-25-warning-letters-june-2026/", "url": "https://glp1tirzepatidereview.com/news/fda-25-warning-letters-june-2026/", "title": "FDA Sends 25 More Warning Letters Over Compounded GLP-1 Marketing Claims", "summary": "The June letters continue a pattern running back to September 2025, and the target is consistent: what providers say their product is.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/foundayo-orforglipron-fda-approval/", "url": "https://glp1tirzepatidereview.com/news/foundayo-orforglipron-fda-approval/", "title": "FDA Approves Foundayo (Orforglipron), the First Small-Molecule Oral GLP-1 for Weight Loss", "summary": "A once-daily pill with no food or water restrictions, available from $149 a month self-pay \u2014 and the lowest mean weight reduction of any approved option.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/wegovy-pill-oral-semaglutide-approval/", "url": "https://glp1tirzepatidereview.com/news/wegovy-pill-oral-semaglutide-approval/", "title": "FDA Approves the Wegovy Pill: Oral Semaglutide 25 mg for Weight Management", "summary": "The first oral GLP-1 approved for weight loss, with cardiovascular risk reduction on the label and results close to the injectable.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/step-up-semaglutide-7-2mg/", "url": "https://glp1tirzepatidereview.com/news/step-up-semaglutide-7-2mg/", "title": "STEP UP: Semaglutide 7.2 mg Reports 20.7% Weight Loss, Narrowing the Gap With Tirzepatide", "summary": "A threefold increase on the approved dose brings semaglutide close to tirzepatide's SURMOUNT-1 figure \u2014 if tolerability holds.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/medicare-glp1-bridge-launches/", "url": "https://glp1tirzepatidereview.com/news/medicare-glp1-bridge-launches/", "title": "Medicare GLP-1 Bridge Opens: $50 a Month for Eligible Part D Enrollees", "summary": "For the first time Medicare covers GLP-1s for weight loss \u2014 through a demonstration programme that expires at the end of 2027 with no confirmed successor.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/balance-model-part-d-delayed/", "url": "https://glp1tirzepatidereview.com/news/balance-model-part-d-delayed/", "title": "CMS Delays the BALANCE Model Indefinitely and Extends the GLP-1 Bridge Instead", "summary": "The programme meant to succeed the Bridge has been postponed without a new date, leaving temporary access with nothing confirmed behind it.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/trumprx-launch-direct-pricing/", "url": "https://glp1tirzepatidereview.com/news/trumprx-launch-direct-pricing/", "title": "TrumpRx Launches Direct GLP-1 Pricing, Undercutting List Prices by Up to Nine Times", "summary": "A direct-to-consumer channel advertising semaglutide tablets from $149 and tirzepatide injections from $299, against list prices above $1,000.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/novocare-wegovy-price-cut/", "url": "https://glp1tirzepatidereview.com/news/novocare-wegovy-price-cut/", "title": "NovoCare Cuts Wegovy Self-Pay Pricing to $349 From $499", "summary": "A 30% reduction on the manufacturer's direct channel, and part of a broader repricing that has reshaped the affordability argument.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/soul-trial-oral-semaglutide-cardiovascular/", "url": "https://glp1tirzepatidereview.com/news/soul-trial-oral-semaglutide-cardiovascular/", "title": "SOUL: Oral Semaglutide Cuts Major Cardiovascular Events by 14% in High-Risk Type 2 Diabetes", "summary": "A 9,647-patient outcomes trial reporting a 14% reduction in MACE and 22% in heart failure events \u2014 a hard-endpoint result in a field dominated by surrogate measures.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/evoke-alzheimers-null-result/", "url": "https://glp1tirzepatidereview.com/news/evoke-alzheimers-null-result/", "title": "EVOKE and EVOKE+: Oral Semaglutide Made No Difference to Alzheimer's Progression", "summary": "A 3,808-patient, two-year programme returned a null result \u2014 and null results in this field deserve more coverage than they get.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/reimagine-2-cagrisema-diabetes/", "url": "https://glp1tirzepatidereview.com/news/reimagine-2-cagrisema-diabetes/", "title": "REIMAGINE 2: CagriSema Beats Semaglutide on HbA1c by 1.91 Points With 14.2% Weight Loss", "summary": "The furthest-advanced next-generation combination reports in type 2 diabetes, ahead of an FDA response expected during 2026.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/synchronize-1-visceral-liver-fat/", "url": "https://glp1tirzepatidereview.com/news/synchronize-1-visceral-liver-fat/", "title": "SYNCHRONIZE-1: 16.6% Weight Loss With 34% Less Visceral Fat and 63% Less Liver Fat", "summary": "A 76-week phase 3 readout measuring where fat is lost, not only how much \u2014 which is the more clinically informative question.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/structure-therapeutics-oral-access-ii/", "url": "https://glp1tirzepatidereview.com/news/structure-therapeutics-oral-access-ii/", "title": "ACCESS II: A Second Oral Small-Molecule GLP-1 Posts 16.3% Placebo-Adjusted Weight Loss", "summary": "Structure Therapeutics reports phase 2 results with no fasting window required \u2014 a direct challenge to oral semaglutide's administration burden.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/fda-peptide-advisory-committee-july-2026/", "url": "https://glp1tirzepatidereview.com/news/fda-peptide-advisory-committee-july-2026/", "title": "FDA Advisory Committee Reviews BPC-157, TB-500 and Five Other Peptides This Week", "summary": "Briefing documents posted in June recommended against adding any of the seven to the 503A compounding list. The committee met on 23 and 24 July.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/generic-tirzepatide-anda-filings/", "url": "https://glp1tirzepatidereview.com/news/generic-tirzepatide-anda-filings/", "title": "Sandoz and Amneal File for Generic Tirzepatide \u2014 But Lilly's Patents Run to 2036", "summary": "An ANDA filing is the start of a legal process, not an imminent launch. Anything sold as generic tirzepatide today is not one.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/fda-february-2026-api-restriction/", "url": "https://glp1tirzepatidereview.com/news/fda-february-2026-api-restriction/", "title": "FDA Signals It Will Restrict GLP-1 Active Ingredients Used in Non-Approved Compounded Products", "summary": "The February announcement was the turn from warning letters to structural action, and the bulks proposal followed twelve weeks later.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/tirzepatide-shortage-timeline-litigation/", "url": "https://glp1tirzepatidereview.com/news/tirzepatide-shortage-timeline-litigation/", "title": "The Tirzepatide Shortage Delisting Was Not One Date \u2014 It Was a Year of Litigation", "summary": "Widely reported as 'October 2024', the delisting was determined, remanded, contested and re-affirmed across five months. We had it wrong too.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/compounded-b12-chemical-bonding-study/", "url": "https://glp1tirzepatidereview.com/news/compounded-b12-chemical-bonding-study/", "title": "A 2026 Study Finds Tirzepatide and B12 Can Chemically Bond \u2014 Forming a Molecule Not in the Approved Drug", "summary": "Additives used to differentiate compounded products from their approved counterparts are largely untested, and at least one interacts.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/surmount-5-published-nejm/", "url": "https://glp1tirzepatidereview.com/news/surmount-5-published-nejm/", "title": "SURMOUNT-5 Published: Tirzepatide 20.2% Against Semaglutide 13.7% in the First Head-to-Head", "summary": "751 adults, 72 weeks, maximum tolerated doses of each \u2014 the only trial that has compared these two drugs directly for weight management.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/summit-hfpef-results/", "url": "https://glp1tirzepatidereview.com/news/summit-hfpef-results/", "title": "SUMMIT: Tirzepatide Cuts Worsening Heart-Failure Events by 38% in Obesity-Related HFpEF", "summary": "A 731-patient phase 3 trial in a specific cardiac phenotype, with imaging substudies supporting a mechanical explanation.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/surmount-1-three-year-diabetes-prevention/", "url": "https://glp1tirzepatidereview.com/news/surmount-1-three-year-diabetes-prevention/", "title": "Three Years of Tirzepatide Markedly Reduced Progression to Type 2 Diabetes in Prediabetes", "summary": "The longest published follow-up in this field: 1,032 participants, 176 weeks of treatment, and a hard clinical endpoint rather than a surrogate.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/zepbound-osa-indication/", "url": "https://glp1tirzepatidereview.com/news/zepbound-osa-indication/", "title": "Zepbound Now Carries an Obstructive Sleep Apnoea Indication Alongside Weight Management", "summary": "The first GLP-1 approved for a sleep disorder, following the SURMOUNT-OSA programme \u2014 and a coverage implication for patients whose plans exclude weight management.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/gallup-glp1-use-obesity-decline/", "url": "https://glp1tirzepatidereview.com/news/gallup-glp1-use-obesity-decline/", "title": "GLP-1 Use Reaches 11% of US Adults as the Obesity Rate Falls to 36.4%", "summary": "Current use has nearly quadrupled in two years. Over the same period national obesity prevalence declined from its 2022 peak.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/ada-2026-bimagrumab-lean-mass/", "url": "https://glp1tirzepatidereview.com/news/ada-2026-bimagrumab-lean-mass/", "title": "ADA 2026: Adding a Myostatin Inhibitor Cut the Lean-Mass Share of Weight Loss From 21% to 7%", "summary": "The first strong signal that the composition of GLP-1 weight loss is pharmacologically modifiable \u2014 with a large gap still open on function.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/ada-2026-osteoarthritis-outcomes/", "url": "https://glp1tirzepatidereview.com/news/ada-2026-osteoarthritis-outcomes/", "title": "ADA 2026: Semaglutide Improved Knee Osteoarthritis Pain \u2014 and Tirzepatide's Extra Weight Loss Did Not Add More", "summary": "Meaningful WOMAC reduction and less analgesic use, with an asymmetry that raises a question about mechanism.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/wegovy-pill-three-million-prescriptions/", "url": "https://glp1tirzepatidereview.com/news/wegovy-pill-three-million-prescriptions/", "title": "The Wegovy Pill Passed Three Million Prescriptions in Just Over Five Months", "summary": "An uptake rate suggesting the oral route addressed a real barrier rather than offering a marginal alternative.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/semaglutide-shortage-resolved-enforcement/", "url": "https://glp1tirzepatidereview.com/news/semaglutide-shortage-resolved-enforcement/", "title": "Semaglutide Came Off the Shortage List in February 2025 \u2014 With a May Deadline for Outsourcing Facilities", "summary": "The delisting closed the pathway that had permitted compounding at scale, on a defined wind-down timetable.", "date_published": "2026-07-24T00:00:00Z" }, { "id": "https://glp1tirzepatidereview.com/news/hims-compounded-wegovy-pill-withdrawal/", "url": "https://glp1tirzepatidereview.com/news/hims-compounded-wegovy-pill-withdrawal/", "title": "A Major Telehealth Platform Withdrew a Compounded Copy of the Wegovy Pill Under Legal Threat", "summary": "The episode is widely cited as the point at which FDA enforcement shifted focus from compounders to the platforms marketing them.", "date_published": "2026-07-24T00:00:00Z" } ] }